CD55

Function

CD55 or complement decay-accelerating factor (DAF) serves as an inhibitor of the complement system. It is broadly expressed in malignant tumors^[1].

Disease

CD55 mutations are related to early-onset protein-losing enteropathy and thrombosis^[2].

Relevance

CD55 is involved in promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, evasion of apoptosis, cell motility and metastasis. CD55 is included in diagnostic or therapeutic studies.

Human CD55 short concensus repeat (SCR) domains dimer complex with sulfate, acetate and glycerol (PDB code 1ojv)

Drag the structure with the mouse to rotate

3D structures of CD553D structures of CD55

Updated on 20-January-2025

3j24, 2qzd, 2qzf, 2qzh - hCD55 - human - Cryo EM
1ojv, 1ojw, 1ojy, 1ok1, 1ok2, 1ok3, 1ok9 - hCD55
1nwv - hCD55 - NMR
1uot, 1h03, 1h2p, 1h2q, 1h04 - hCD55 domains 3,4
1m11, 3iyp, 2c8i, 1upn, 6ilj, 6ilk, 6la5, 6lao, 7c9w, 8b8r, 8b9f - hCD55 + echovirus - Cryo EM
7vy5, 7vy6 - hCD55 + coxsakievirus - Cryo EM
5foa - hCD55 + complement C3 + complement C3B
7do4 - hCD55 + CD97

ReferencesReferences

↑ Mikesch JH, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta. 2006 Aug;1766(1):42-52. doi: 10.1016/j.bbcan.2006.04.001., Epub 2006 May 9. PMID:16784816 doi:http://dx.doi.org/10.1016/j.bbcan.2006.04.001
↑ Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017 Jul 6;377(1):52-61. doi: 10.1056/NEJMoa1615887. Epub 2017 Jun , 28. PMID:28657829 doi:http://dx.doi.org/10.1056/NEJMoa1615887

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel

[1] Mikesch JH, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta. 2006 Aug;1766(1):42-52. doi: 10.1016/j.bbcan.2006.04.001., Epub 2006 May 9. PMID:16784816 doi:http://dx.doi.org/10.1016/j.bbcan.2006.04.001

[2] Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017 Jul 6;377(1):52-61. doi: 10.1056/NEJMoa1615887. Epub 2017 Jun , 28. PMID:28657829 doi:http://dx.doi.org/10.1056/NEJMoa1615887

[1]

[2]